Cross-validation of ELISA and a portable surface plasmon resonance instrument for IgG antibody serology with SARS-CoV-2 positive individuals
Cross-validation of ELISA and a portable surface plasmon resonance instrument for IgG antibody serology with SARS-CoV-2 positive individuals
复制标题
DOI：
10.1039/d1an00893e
复制
发表时间：
2021-07-01
期刊：
影响因子：
4.2
通讯作者：
Masson, Jean-Francois
中科院分区：
文献类型：
--
作者：
Djaileb, Abdelhadi;Jodaylami, Maryam Hojjat;Masson, Jean-Francois
我们报告了表面等离子共振 (SPR) 传感器和匹配 ELISA 的开发，用于检测人血清、血浆和干血斑 (DBS) 中针对 2019 新型冠状病毒 (SARS-CoV-2) 的核衣壳和刺突抗体。当接触 SARS-CoV-2 或针对 SARS-CoV-2 的疫苗时，免疫系统会通过表达可检测和监测水平的抗体来做出反应，以识别可能对 SARS-CoV-2 免疫的人群比例，并支持战略性部署疫苗的努力。涂有单层肽并用在不同细胞系中表达的各种来源的 SARS-CoV-2 重组蛋白进行功能化的 SPR 传感器检测到临床样本中的人类抗 SARS-CoV-2 IgG 抗体。在不同细胞系中表达的核衣壳并没有显着改变测定的灵敏度，而使用 CHO 细胞系表达刺突胞外域则获得了优异的性能。该生物测定是在便携式 SPR 仪器上进行的，该仪器能够在样品/传感器接触后 30 分钟内测量 4 个生物样品，并且芯片可以再生至少 9 次。然后使用内部和商业 ELISA 进行多位点验证，结果表明，对于 DBS 和血浆中的测量，在所有情况下与 Pearson 系数都超过 0.85。该策略为病毒感染和疫苗功效监测背景下的抗体即时检测和快速检测铺平了道路。
We report on the development of surface plasmon resonance (SPR) sensors and matching ELISAs for the detection of nucleocapsid and spike antibodies specific against the novel coronavirus 2019 (SARS-CoV-2) in human serum, plasma and dried blood spots (DBS). When exposed to SARS-CoV-2 or a vaccine against SARS-CoV-2, the immune system responds by expressing antibodies at levels that can be detected and monitored to identify the fraction of the population potentially immunized against SARS-CoV-2 and support efforts to deploy a vaccine strategically. A SPR sensor coated with a peptide monolayer and functionalized with various sources of SARS-CoV-2 recombinant proteins expressed in different cell lines detected human anti-SARS-CoV-2 IgG antibodies in clinical samples. Nucleocapsid expressed in different cell lines did not significantly change the sensitivity of the assays, whereas the use of a CHO cell line to express spike ectodomain led to excellent performance. This bioassay was performed on a portable SPR instrument capable of measuring 4 biological samples within 30 minutes of sample/sensor contact and the chip could be regenerated at least 9 times. Multi-site validation was then performed with in-house and commercial ELISA, which revealed excellent cross-correlations with Pearson's coefficients exceeding 0.85 in all cases, for measurements in DBS and plasma. This strategy paves the way to point-of-care and rapid testing for antibodies in the context of viral infection and vaccine efficacy monitoring.